Revolutionizing Urology
Revolutionizing Urology: How Vesiflo’s inFlow™ Prosthesis is Disrupting the Urinary Catheter Market
Everyone knows what a big issue urinary incontinence is, but imagine the opposite problem, being unable to void. When urinary retention occurs, it is considered a serious medical condition and is always at least initially treated with urinary catheterization – but no one wants to use a catheter. Vesiflo’s mission is to reinvent urinary catheters, disrupting a very large market that has seen little in the way of innovation.
Vesiflo’s inFlow™ voiding prosthesis™ (“inFlow”) is the first medical alternative to catheters – and it is a safer, more convenient and significantly more dignified option. The inFlow is for women whose bladder function has been impaired by life-changing neurologic conditions such as MS, spinal cord injury, spina bifida, diabetes, etc. who would otherwise have to use catheters on a life-long basis. Initial response to inFlow has been overwhelming, with users describing it as “life changing” relative to catheterization. The inFlow is FDA approved and as of January 1, 2025, is expected to be reimbursed by Medicare.
Based on a conservative estimate of the number of device candidates and the device price proposed by CMS, the inFlow’s TAM in the U.S. is $1.5 Billion/year. Because its users have incurable conditions and need a new device every month, the typical inFlow user generates recurring revenues of ~$6,000 annually (12 devices @ $495 each).
Vesiflo is headed by Kevin Connolly, an industry veteran and thought leader in female urology who previously founded and operated four (4) medical device manufacturing companies. Most recently, Mr. Connolly was Founder and CEO of www.srsmedical.com, where he acquired and developed a comprehensive product line for the diagnosis and conservative treatment of incontinence and other voiding disorders, including some of the most innovative urodynamics systems in the industry. Accomplishments while at Vesiflo include 4 issued patents, 2 peer-reviewed journal articles, 3 podium presentations at medical conferences, FDA approval of the inFlow and now Medicare reimbursement at appropriate payment rates.
This is a unique opportunity for the SFOG community to participate in a de-risked medtech company that is about to enter its growth phase. We look forward to seeing you on our upcoming SFOG webinar in September.
To learn more please contact Spotlight Family Office Group at Info@SpotlightFamilyOffice.com.